

RESULTS OF EXTRAORDINARY GENERAL MEETING

Extraordinary general meeting in Forward Pharma A/S (the "Company") was held on 25 February 2025 at the offices of Mazanti-Andersen Advokatpartnerselskab, Amaliegade 10, 1265 Copenhagen K, Denmark (the "General Meeting"). DKK 680,172.72 of the Company's voting share capital and 68,017,272 votes, respectively, (excl. the Company's holding of own shares) were represented at the General Meeting.

Results of the General Meeting were as follows:

- (a) Adoption of the proposal to pass a resolution for the voluntary solvent liquidation of the Company in accordance with the Danish Companies Act, including to appoint Jakob Mosegaard Larsen, attorney-at-law, as liquidator by 68,017,272 votes in favour, and with 0 votes against and 0 abstentions.
- (b) Adoption of the proposal to authorize the liquidator (with a right of substitution) on behalf of the Company to apply the Danish Business Authority for registration of the resolutions passed and in this connection to make any such amendments and supplements to the application and the resolution, including the Company's Articles of Association and these minutes of the general meeting, that may be required as a condition for registration by 68,017,272 votes in favour, and with 0 votes against and 0 abstentions.